Volcano gets to Crux of $300m peripheral embolism market with $36m acquisition
This article was originally published in Clinica
Volcano, which specialises in devices for facilitating endovascular procedures, has entered the peripheral vascular market by agreeing to acquire privately-held Crux Biomedical for $36 million in cash. Volcano (San Diego, California) will also pay up to $3.1 million in transaction expenses, and a milestone payment of $3.0 million upon US FDA clearance of a 510(k) application submitted by Volcano on or before June 30 2013, for a retrieval device currently being developed by Crux.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.